ArticleCNS neuroscience & therapeutics2026
Apoptin-Derived Peptide Alleviates Temporal Lobe Epilepsy (TLE) by Limiting Neuronal Ca
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
aimsTo determine whether the apoptin-derived peptide (also named B9) reduces evoked seizure susceptibility and kainic acid (KA)-associated cognitive and molecular abnormalities, and to define whether these effects involve the heat shock protein family A member 1A (HSPA1A)-adaptor protein complex 2 subunit beta 1 (AP2B1) pathway.
methodsThe therapeutic efficacy of B9 was examined in a pentylenetetrazol (PTZ)-induced acute seizure model and a KA-induced temporal lobe epilepsy (TLE) model. Electroencephalographic (EEG) recordings were performed to evaluate epileptiform activity. The Barnes maze test was used to assess cognitive function in epileptic mice. Western blotting, co-immunoprecipitation (Co-IP), immunofluorescence (IF), and calcium imaging were used to investigate the underlying mechanism.
resultsB9 reduced seizure susceptibility, attenuated epileptiform activity, and improved spatial learning and memory. HSPA1A was markedly upregulated in TLE-related datasets and experimental models. B9 suppressed the expression of HSPA1A and disrupted its interaction with AP2B1, which restored O-linked β-N-acetylglucosamine (O-GlcNAc) modification and protein stability of AP2B1, preserved GluA2 expression, and limited neuronal Ca
conclusionB9 reduces PTZ-evoked seizure susceptibility and ameliorates KA-associated cognitive and molecular abnormalities through modulation of the HSPA1A-AP2B1 axis. These findings support B9 as a potential therapeutic strategy for TLE.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.